All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Bookmark this article
The ALL Hub is pleased to present a visual abstract representing key data from the phase II HOVON146ALL trial (NCT03541083), evaluating blinatumomab added to prephase and consolidation therapy in newly diagnosed patients with ALL.
To download this visual abstract, click below.Download here
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
During the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to...
Current recommendations for therapy-related toxicity management in ALL
Despite the great clinical advances in the field of acute lymphoblastic leukemia (ALL), novel therapies have led to the emergence of unique toxicities that need to be...
Subscribe to get the best content related to ALL delivered to your inbox